A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

Trial Profile

A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs ASP 4070 (Primary)
  • Indications Allergic rhinoconjunctivitis; Tree pollen hypersensitivity
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Jul 2013 Status changed from recruiting to completed, as reported in an Immunomic Therapeutics media release.
    • 24 Apr 2013 Immunomic Therapeutics is planning to continue collecting data for about the next 30 days and will have a more complete report available later in 2013, according to a company media release.
    • 24 Apr 2013 Interim results (n=24) published in an Immunomic Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top